Aggressive behavior increases after termination of chronic sildenafil treatment in mice.
Recent reports to the U.S. Food and Drug Administration Adverse Event Reporting System implicate sildenafil citrate in adverse emotional and aggressive behaviors. Sildenafil citrate (Viagra) is widely prescribed for erectile dysfunction and acts by inhibiting phosphodiesterase Type-5, resulting in accumulation of cyclic-guanosine monophosphate (cGMP). Cyclic-GMP is synthesized by guanylyl cyclase that is directly activated by the messenger molecule, nitric oxide (NO), formed throughout the CNS by the enzyme nitric oxide synthase (NOS). Elevated concentrations of cGMP have been associated with increased aggressive behavior. In addition, the potential effect of cGMP accumulation on NO-mediated behavioral and neuroendocrine function through possible feedback mechanisms remains unspecified; however, neuronal NOS (nNOS) inhibition by pharmacologic agents or ablation of the gene encoding nNOS increases aggressive behavior in male mice. We tested the hypothesis that sildenafil citrate may increase aggression via its actions on cGMP and potential feedback inhibition of NO concentrations. Male C57BL/6 mice were injected with saline vehicle (0), 2, 5, 8, or 10 mg/kg of sildenafil citrate thrice weekly for 4 weeks. Latency to display aggressive behavior, frequency, and duration of aggressive behavior were recorded during neutral-arena aggression tests. No change in agonistic behavior was observed in mice during treatment with sildenafil citrate. However, sildenafil-treated mice given the highest dose were generally more aggressive 1 week post-cessation of drug treatment as compared to vehicle-treated mice. Additional investigation into potential withdrawal effects or abuse doses seems warranted.
Hotchkiss
Andrew K
AK
Department of Psychology, Ohio State University, Columbus, OH 43210, USA.
Pyter
Leah M
LM
Gatien
Michelle L
ML
Wen
Jarvi C
JC
Milman
Harry A
HA
Nelson
Randy J
RJ
D000374:Aggression / Q000187:drug effects*; D000818:Animals; D006152:Cyclic GMP / Q000378:metabolism; D016018:Least-Squares Analysis; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010879:Piperazines / Q000009:adverse effects*; D011687:Purines; D000068677:Sildenafil Citrate; D013375:Substance Withdrawal Syndrome / Q000523:psychology*; D013450:Sulfones; D013997:Time Factors; D014665:Vasodilator Agents / Q000009:adverse effects*
D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D006152:Cyclic GMP